Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in: Pituitary 2/2020

01-04-2020 | Prolactinoma

A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas

Authors: B. G. Sant’ Anna, N. R. C. Musolino, M. R. Gadelha, C. Marques, M. Castro, P. C. L. Elias, L. Vilar, R. Lyra, M. R. A. Martins, A. R. P. Quidute, J. Abucham, D. Nazato, H. M. Garmes, M. L. C. Fontana, C. L. Boguszewski, C. B. Bueno, M. A. Czepielewski, E. S. Portes, V. S. Nunes-Nogueira, A. Ribeiro-Oliveira Jr., R. P. V. Francisco, M. D. Bronstein, A. Glezer

Published in: Pituitary | Issue 2/2020

Login to get access

Abstract

Objective

To evaluate the maternal–fetal outcomes of CAB-induced pregnancies in patients with prolactinoma in a large cohort.

Methods

The prevalence of tumor growth, miscarriage, preterm, low birth weight, congenital malformations and impairment in neuropsychological development in children among women treated with CAB were assessed in a Brazilian multicentre retrospective observational study,

Results

We included 194 women with a mean age of 31 (17–45) years, 43.6% presenting microadenomas and 56.4% macroadenomas, at prolactinoma diagnosis. In 233 pregnancies, CAB was withdrawn in 89%, after pregnancy confirmation. Symptoms related to tumor growth occurred in 25 cases, more frequently in macroadenomas. The overall miscarriage rate was 11%, although higher in the subgroup of patients with CAB maintainance after pregnancy confirmation (38% vs. 7.5%). Amongst the live-birth deliveries, preterm occurred in 12%, low birth weight in 6% and congenital malformations in 4.3%. Neuropsychological development impairment was reported in 7% of cases.

Conclusions

Our findings confirm previous results of safety in maternal and fetal outcomes in CAB-induced pregnancies; nevertheless, CAB maintenance after pregnancy confirmation was associated with higher miscarriage rate; result that must be further confirmed.
Literature
1.
Miyai K, Ichihara K, Kondo K, Mori S (1986) Asymptomatic hyperprolactinaemia and prolactinoma in the general population–mass screening by paired assays of serum prolactin. Clin Endocrinol 25(5):549–554
2.
Hardy J (1969) Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg. 16:185–217PubMed
3.
Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD et al (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325–331PubMed
4.
Robert E, Musatti L, Piscitelli G, Ferrari CI (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10(4):333–337PubMed
5.
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331(14):904–909PubMed
6.
Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A et al (1986) Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 63(4):941–945PubMed
7.
Molitch ME (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary 5(2):55–65PubMed
8.
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288PubMed
9.
Mehta AE, Tolis G (1979) Pharmacology of bromocriptine in health and disease. Drugs 17(5):313–325PubMed
10.
Krupp P, Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65(17):823–827PubMed
11.
Molitch ME (2015) Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol 172(5):R205–R213PubMed
12.
Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ (1988) Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med 85(2):217–220PubMed
13.
Hu Y, Ding Y, Yang M, Xiang Z (2018) Serum prolactin levels across pregnancy and the establishment of reference intervals. Clin Chem Lab Med 56(5):803–807PubMed
14.
Scheithauer BW, Sano T, Kovacs KT, Young WF, Ryan N, Randall RV (1990) The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 65(4):461–474PubMed
15.
Persiani S, Sassolas G, Piscitelli G, Bizollon CA, Poggesi I, Pianezzola E et al (1994) Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. J Pharm Sci 83(10):1421–1424PubMed
16.
Bigazzi M, Ronga R, Lancranjan I, Ferraro S, Branconi F, Buzzoni P et al (1979) A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments. J Clin Endocrinol Metab 48(1):9–12PubMed
17.
Beltrame D, Longo M, Mazué G (1996) Reproductive toxicity of cabergoline in mice, rats, and rabbits. Reprod Toxicol 10(6):471–483PubMed
18.
Molitch ME (1999) Management of prolactinomas during pregnancy. J Reprod Med 44(12 Suppl):1121–1126PubMed
19.
Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol 73(2):236–242
20.
Stalldecker G, Mallea-Gil MS, Guitelman M, Alfieri A, Ballarino MC, Boero L et al (2010) Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 13(4):345–350PubMed
21.
Bronstein MD (2005) Prolactinomas and pregnancy. Pituitary 8(1):31–38PubMed
22.
Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R et al (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95(6):2672–2679PubMed
23.
Raymond JP, Goldstein E, Konopka P, Leleu MF, Merceron RE, Loria Y (1985) Follow-up of children born of bromocriptine-treated mothers. Horm Res 22(3):239–246PubMed
24.
Bronstein MD, Salgado LR, de Castro Musolino NR (2002) Medical management of pituitary adenomas: the special case of management of the pregnant woman. Pituitary 5(2):99–107PubMed
25.
Karaca Z, Yarman S, Ozbas I, Kadioglu P, Akturk M, Kilicli F et al (2018) How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey. J Endocrinol Investig 41(1):129–141
26.
Rastogi A, Bhadada SK, Bhansali A (2017) Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecol Endocrinol 33(4):270–273PubMed
27.
Galvão A, Gonçalves D, Moreira M, Inocêncio G, Silva C, Braga J (2017) Prolactinoma and pregnancy—a series of cases including pituitary apoplexy. J Obstet Gynaecol 37(3):284–287PubMed
28.
Araujo B, Belo S, Carvalho D (2017) Pregnancy and Tumor Outcomes in Women with Prolactinoma. Exp Clin Endocrinol Diabetes 125(10):642–648PubMed
29.
Lambert K, Rees K, Seed PT, Dhanjal MK, Knight M, McCance DR et al (2017) Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes. Obstet Gynecol 129(1):185–194PubMed
30.
Glezer A, Bronstein MD (2017) Prolactinomas: how to handle prior to and during pregnancy? Minerva Endocrinol 43(4):423–429PubMed
31.
Molitch ME (1985) Pregnancy and the hyperprolactinemic woman. N Engl J Med 312(21):1364–1370PubMed
32.
Gemzell C, Wang CF (1979) Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 31(4):363–372PubMed
33.
Holmgren U, Bergstrand G, Hagenfeldt K, Werner S (1986) Women with prolactinoma–effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol 111(4):452–459PubMed
34.
Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, Canfield RE et al (1988) Incidence of early loss of pregnancy. N Engl J Med 319(4):189–194PubMed
35.
Hemminki E, Forssas E (1999) Epidemiology of miscarriage and its relation to other reproductive events in Finland. Am J Obstet Gynecol 181(2):396–401PubMed
36.
Cecatti JG, Guerra GV, Sousa MH, Menezes GM (2010) Abortion in Brazil: a demographic approach. Rev Bras Ginecol Obstet 32(3):105–111PubMed
37.
Sedgh G, Bearak J, Singh S, Bankole A, Popinchalk A, Ganatra B et al (2016) Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. Lancet 388(10041):258–267PubMedPubMedCentral
38.
Hurault-Delarue C, Montastruc JL, Beau AB, Lacroix I, Damase-Michel C (2014) Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet 290(2):263–270PubMed
39.
Bachelot A, Binart N (2007) Reproductive role of prolactin. Reproduction 133(2):361–369PubMed
40.
Iwama S, Welt CK, Romero CJ, Radovick S, Caturegli P (2013) Isolated prolactin deficiency associated with serum autoantibodies against prolactin-secreting cells. J Clin Endocrinol Metab 98(10):3920–3925PubMedPubMedCentral
41.
Vila G, Akerblad AC, Mattsson AF, Riedl M, Webb SM, Hána V et al (2015) Pregnancy outcomes in women with growth hormone deficiency. Fertil Steril 104(5):1210–7.e1PubMed
42.
Betrán AP, Ye J, Moller AB, Zhang J, Gülmezoglu AM, Torloni MR (2016) The increasing trend in caesarean section rates: global, regional and national estimates: 1990–2014. PLoS ONE 11(2):e0148343PubMedPubMedCentral
43.
Ferreira EC, Pacagnella RC, Costa ML, Cecatti JG (2015) The Robson ten-group classification system for appraising deliveries at a tertiary referral hospital in Brazil. Int J Gynaecol Obstet 129(3):236–239PubMed
44.
Bolognani CV, Reis LBSM, Dias A, Calderon IMP (2018) Robson 10-groups classification system to access C-section in two public hospitals of the Federal District/Brazil. PLoS ONE 13(2):e0192997PubMedPubMedCentral
45.
Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A et al (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16(6):791–793PubMed
46.
Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol 68(1):66–71
47.
Domingue ME, Devuyst F, Alexopoulou O, Corvilain B, Maiter D (2014) Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol 80(5):642–648
48.
Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R et al (2012) National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 379(9832):2162–2172PubMed
49.
Blanc AK, Wardlaw T (2005) Monitoring low birth weight: an evaluation of international estimates and an updated estimation procedure. Bull World Health Organ 83(3):178–185PubMedPubMedCentral
50.
Kalter H, Warkany J (1983) Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts). N Engl J Med 308(8):424–431PubMed
51.
Glezer A, Bronstein MD (2014) Prolactinomas, cabergoline, and pregnancy. Endocrine 47(1):64–69PubMed
52.
Mitsiakos G (2019) A possible role of GDNF expression by which cabergoline use affects corpus callosum. J Pediatr Neonatal Individ Med 8:e080112
53.
van Gool JD, Hirche H, Lax H, De Schaepdrijver L (2018) Folic acid and primary prevention of neural tube defects: a review. Reprod Toxicol 80:73–84PubMed
54.
Zárate A, Canales ES, Alger M, Forsbach G (1979) The effect of pregnancy and lactation on pituitary prolactin-secreting tumours. Acta Endocrinol 92(3):407–412PubMed
55.
Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M et al (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98(1):372–379PubMed
56.
Rjosk HK, Fahlbusch R, von Werder K (1982) Influence of pregnancies on prolactinomas. Acta Endocrinol 100(3):337–346PubMed
57.
Crosignani PG, Mattei AM, Scarduelli C, Cavioni V, Boracchi P (1989) Is pregnancy the best treatment for hyperprolactinaemia? Hum Reprod 4(8):910–912PubMed
58.
Crosignani PG, Mattei AM, Severini V, Cavioni V, Maggioni P, Testa G (1992) Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol 44(3):175–180PubMed
59.
Huda MS, Athauda NB, Teh MM, Carroll PV, Powrie JK (2010) Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol 72(4):507–511
Metadata
Title
A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas
Authors
B. G. Sant’ Anna
N. R. C. Musolino
M. R. Gadelha
C. Marques
M. Castro
P. C. L. Elias
L. Vilar
R. Lyra
M. R. A. Martins
A. R. P. Quidute
J. Abucham
D. Nazato
H. M. Garmes
M. L. C. Fontana
C. L. Boguszewski
C. B. Bueno
M. A. Czepielewski
E. S. Portes
V. S. Nunes-Nogueira
A. Ribeiro-Oliveira Jr.
R. P. V. Francisco
M. D. Bronstein
A. Glezer
Publication date
01-04-2020
Publisher
Springer US
Published in
Pituitary / Issue 2/2020
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-019-01008-z

Other articles of this Issue 2/2020

Pituitary 2/2020 Go to the issue

OriginalPaper

Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study

OriginalPaper

Semen quality in hypogonadal acromegalic patients

OriginalPaper

Long-term follow-up for ectopic ACTH-secreting pituitary adenoma in a single tertiary medical center and a literature review

ReviewPaper

Surgical indications for pituitary tumors during pregnancy: a literature review

Letter

Effects of cabergoline therapy on serum IGF-1 concentrations in prolactinoma patients

ReviewPaper

Granulomatous hypophysitis causing compression of the internal carotid arteries reversible with azathioprine and rituximab treatment
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits